{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T03:44:13Z","timestamp":1785469453895,"version":"3.56.0"},"reference-count":161,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,9,16]],"date-time":"2022-09-16T00:00:00Z","timestamp":1663286400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004595","name":"Universiti Sains Malaysia","doi-asserted-by":"publisher","award":["RUI 1001\/CIPPM\/8011050"],"award-info":[{"award-number":["RUI 1001\/CIPPM\/8011050"]}],"id":[{"id":"10.13039\/501100004595","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003093","name":"Ministry of Higher Education, Malaysia","doi-asserted-by":"publisher","award":["203\/CIPPM\/6711968"],"award-info":[{"award-number":["203\/CIPPM\/6711968"]}],"id":[{"id":"10.13039\/501100003093","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedical Engineering Advances"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.bea.2022.100054","type":"journal-article","created":{"date-parts":[[2022,9,18]],"date-time":"2022-09-18T01:17:50Z","timestamp":1663463870000},"page":"100054","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Single domain antibodies derived from ancient animals as broadly neutralizing agents for SARS-CoV-2 and other coronaviruses"],"prefix":"10.1016","volume":"4","author":[{"given":"H.T.","family":"Lim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.H.","family":"Kok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.P.","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.B.","family":"Abdul Majeed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.Y.","family":"Leow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0849-428X","authenticated-orcid":false,"given":"C.H.","family":"Leow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7798","key":"10.1016\/j.bea.2022.100054_bib0001","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41586-020-2012-7","article-title":"A pneumonia outbreak associated with a new coronavirus of probable bat origin","volume":"579","author":"Zhou","year":"2020","journal-title":"Nature"},{"issue":"12","key":"10.1016\/j.bea.2022.100054_bib0002","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1038\/nm.3985","article-title":"A SARS-like cluster of circulating bat coronaviruses shows potential for human emergence","volume":"21","author":"Menachery","year":"2015","journal-title":"Nat. Med."},{"issue":"7","key":"10.1016\/j.bea.2022.100054_bib0003","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/S2213-2600(20)30229-0","article-title":"Management of acute kidney injury in patients with COVID-19","volume":"8","author":"Ronco","year":"2020","journal-title":"Lancet Respir. Med."},{"issue":"1","key":"10.1016\/j.bea.2022.100054_bib0004","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41421-019-0132-8","article-title":"Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro","volume":"6","author":"Liu","year":"2020","journal-title":"Cell Discov."},{"issue":"1","key":"10.1016\/j.bea.2022.100054_bib0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2020.105949","article-title":"Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial","volume":"56","author":"Gautret","year":"2020","journal-title":"Int. J. Antimicrob. Agents"},{"issue":"9","key":"10.1016\/j.bea.2022.100054_bib0006","doi-asserted-by":"crossref","first-page":"e01101","DOI":"10.1128\/AAC.01101-20","article-title":"Clinical trials of repurposed antivirals for SARS-CoV-2","volume":"64","author":"Martinez","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"issue":"19","key":"10.1016\/j.bea.2022.100054_bib0007","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1056\/NEJMoa2001282","article-title":"A trial of lopinavir\u2013ritonavir in adults hospitalized with severe COVID-19","volume":"382","author":"Cao","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bea.2022.100054_bib0008","first-page":"9","article-title":"The journey of remdesivir: from Ebola to COVID-19","author":"Pardo","year":"2020","journal-title":"Drugs Context"},{"issue":"19","key":"10.1016\/j.bea.2022.100054_bib0009","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMoa2007764","article-title":"Remdesivir for the treatment of COVID-19\u2014preliminary report","volume":"383","author":"Beigel","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"10236","key":"10.1016\/j.bea.2022.100054_bib0010","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/S0140-6736(20)31022-9","article-title":"Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial","volume":"395","author":"Wang","year":"2020","journal-title":"Lancet N. Am. Ed."},{"issue":"7837","key":"10.1016\/j.bea.2022.100054_bib0011","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1038\/d41586-020-03441-8","article-title":"The UK has approved a COVID vaccine-here's what scientists now want to know","volume":"588","author":"Ledford","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.bea.2022.100054_bib0012","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.3389\/fimmu.2020.585354","article-title":"A review of the progress and challenges of developing a vaccine for COVID-19","volume":"11","author":"Sharma","year":"2020","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.bea.2022.100054_bib0013","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-020-79036-0","article-title":"High affinity nanobodies block SARS-CoV-2 spike receptor binding domain interaction with human angiotensin converting enzyme","volume":"10","author":"Esparza","year":"2020","journal-title":"Sci. Rep."},{"issue":"16","key":"10.1016\/j.bea.2022.100054_bib0014","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1001\/jama.2020.4783","article-title":"Treatment of 5 critically ill patients with COVID-19 with convalescent plasma","volume":"323","author":"Shen","year":"2020","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.bea.2022.100054_bib0015","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.7150\/ijbs.59149","article-title":"Development and application of therapeutic antibodies against COVID-19","volume":"17","author":"Ning","year":"2021","journal-title":"Int. J. Biol. Sci."},{"key":"10.1016\/j.bea.2022.100054_bib0016","unstructured":"Mode, D. and L.C. Stockholm, AstraZeneca: Evusheld (formerly AZD7442) long-acting antibody combination authorised for emergency use in the US for pre-exposure prophylaxis (prevention) of COVID-19. 2022."},{"key":"10.1016\/j.bea.2022.100054_bib0017","unstructured":"FDA. Coronavirus (COVID-19) update: FDA authorizes new monoclonal antibody for treatment of COVID-19 that retains activity against Omicron variant. 2022 25 February 2022]; Available from: https:\/\/www.fda.gov\/news-events\/press-announcements\/coronavirus-covid-19-update-fda-authorizes-new-monoclonal-antibody-treatment-covid-19-retains."},{"issue":"10229","key":"10.1016\/j.bea.2022.100054_bib0018","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1016\/S0140-6736(20)30673-5","article-title":"COVID-19: towards controlling of a pandemic","volume":"395","author":"Bedford","year":"2020","journal-title":"Lancet N. Am. Ed."},{"issue":"4","key":"10.1016\/j.bea.2022.100054_bib0019","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.bj.2020.04.007","article-title":"COVID-19: the first documented coronavirus pandemic in history","volume":"43","author":"Liu","year":"2020","journal-title":"Biomed. J."},{"issue":"1","key":"10.1016\/j.bea.2022.100054_bib0020","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1002\/mco2.60","article-title":"A potent neutralizing nanobody against SARS-CoV-2 with inhaled delivery potential","volume":"2","author":"Gai","year":"2021","journal-title":"MedComm"},{"issue":"10292","key":"10.1016\/j.bea.2022.100054_bib0021","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1016\/S0140-6736(21)01290-3","article-title":"Neutralising antibody activity against SARS-CoV-2 VOCs B. 1.617. 2 and B. 1.351 by BNT162b2 vaccination","volume":"397","author":"Wall","year":"2021","journal-title":"Lancet N. Am. Ed."},{"key":"10.1016\/j.bea.2022.100054_bib0022","doi-asserted-by":"crossref","unstructured":"Darby, A.C. and J.A. Hiscox, COVID-19: variants and vaccination. 2021, British Medical Journal Publishing Group.","DOI":"10.1136\/bmj.n771"},{"key":"10.1016\/j.bea.2022.100054_bib0023","unstructured":"WHO. Tracking SARS-CoV-2 variants. 2022 5 September 2022]; Available from: https:\/\/www.who.int\/en\/activities\/tracking-SARS-CoV-2-variants\/."},{"issue":"7855","key":"10.1016\/j.bea.2022.100054_bib0024","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1038\/s41586-021-03324-6","article-title":"mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants","volume":"592","author":"Wang","year":"2021","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.bea.2022.100054_bib0025","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1016\/j.cell.2021.01.037","article-title":"Circulating SARS-CoV-2 spike N439K variants maintain fitness while evading antibody-mediated immunity","volume":"184","author":"Thomson","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.bea.2022.100054_bib0026","unstructured":"WHO. WHO coronavirus (COVID-19) dashboard. 2022 5 September 2022]; Available from: https:\/\/covid19.who.int\/."},{"issue":"10","key":"10.1016\/j.bea.2022.100054_bib0027","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.3181\/0903-MR-94","article-title":"Coronavirus diversity, phylogeny and interspecies jumping","volume":"234","author":"Woo","year":"2009","journal-title":"Exp. Biol. Med."},{"issue":"8","key":"10.1016\/j.bea.2022.100054_bib0028","doi-asserted-by":"crossref","first-page":"2940","DOI":"10.1128\/JCM.00636-10","article-title":"Epidemiology and clinical presentations of the four human coronaviruses 229E, HKU1, NL63, and OC43 detected over 3 years using a novel multiplex real-time PCR method","volume":"48","author":"Gaunt","year":"2010","journal-title":"J. Clin. Microbiol."},{"issue":"20","key":"10.1016\/j.bea.2022.100054_bib0029","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1056\/NEJMoa030781","article-title":"A novel coronavirus associated with severe acute respiratory syndrome","volume":"348","author":"Ksiazek","year":"2003","journal-title":"N. Engl. J. Med."},{"issue":"19","key":"10.1016\/j.bea.2022.100054_bib0030","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1056\/NEJMoa1211721","article-title":"Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia","volume":"367","author":"Zaki","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"10224","key":"10.1016\/j.bea.2022.100054_bib0031","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0140-6736(20)30251-8","article-title":"Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding","volume":"395","author":"Lu","year":"2020","journal-title":"Lancet N. Am. Ed."},{"issue":"9","key":"10.1016\/j.bea.2022.100054_bib0032","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1038\/s41594-020-0469-6","article-title":"Neutralizing nanobodies bind SARS-CoV-2 spike RBD and block interaction with ACE2","volume":"27","author":"Huo","year":"2020","journal-title":"Nat. Struct. Mol. Biol."},{"issue":"2","key":"10.1016\/j.bea.2022.100054_bib0033","doi-asserted-by":"crossref","first-page":"62","DOI":"10.36233\/0507-4088-2020-65-2-62-70","article-title":"Source of the COVID-19 pandemic: ecology and genetics of coronaviruses (Betacoronavirus: Coronaviridae) SARS-CoV, SARS-CoV-2 (subgenus Sarbecovirus), and MERS-CoV (subgenus Merbecovirus)","volume":"65","author":"Lvov","year":"2020","journal-title":"Vopr. Virusol."},{"issue":"3","key":"10.1016\/j.bea.2022.100054_bib0034","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.chom.2020.02.001","article-title":"Genome composition and divergence of the novel coronavirus (2019-nCoV) originating in China","volume":"27","author":"Wu","year":"2020","journal-title":"Cell Host Microbe"},{"issue":"6483","key":"10.1016\/j.bea.2022.100054_bib0035","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1126\/science.abb2507","article-title":"Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation","volume":"367","author":"Wrapp","year":"2020","journal-title":"Science"},{"issue":"5","key":"10.1016\/j.bea.2022.100054_bib0036","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1016\/j.cell.2020.04.031","article-title":"Structural basis for potent neutralization of betacoronaviruses by single-domain camelid antibodies","volume":"181","author":"Wrapp","year":"2020","journal-title":"Cell"},{"issue":"6485","key":"10.1016\/j.bea.2022.100054_bib0037","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1126\/science.abb2762","article-title":"Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2","volume":"367","author":"Yan","year":"2020","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.bea.2022.100054_bib0038","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.cell.2020.02.052","article-title":"SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor","volume":"181","author":"Hoffmann","year":"2020","journal-title":"Cell"},{"issue":"2","key":"10.1016\/j.bea.2022.100054_bib0039","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.cell.2020.02.058","article-title":"Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein","volume":"181","author":"Walls","year":"2020","journal-title":"Cell"},{"issue":"35","key":"10.1016\/j.bea.2022.100054_bib0040","doi-asserted-by":"crossref","first-page":"E7348","DOI":"10.1073\/pnas.1707304114","article-title":"Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen","volume":"114","author":"Pallesen","year":"2017","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"1","key":"10.1016\/j.bea.2022.100054_bib0041","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/cr.2016.152","article-title":"Cryo-electron microscopy structures of the SARS-CoV spike glycoprotein reveal a prerequisite conformational state for receptor binding","volume":"27","author":"Gui","year":"2017","journal-title":"Cell Res."},{"issue":"5","key":"10.1016\/j.bea.2022.100054_bib0042","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1016\/j.cell.2018.12.028","article-title":"Unexpected receptor functional mimicry elucidates activation of coronavirus fusion","volume":"176","author":"Walls","year":"2019","journal-title":"Cell"},{"issue":"7807","key":"10.1016\/j.bea.2022.100054_bib0043","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1038\/s41586-020-2179-y","article-title":"Structural basis of receptor recognition by SARS-CoV-2","volume":"581","author":"Shang","year":"2020","journal-title":"Nature"},{"issue":"19","key":"10.1016\/j.bea.2022.100054_bib0044","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2101918118","article-title":"Nanobody cocktails potently neutralize SARS-CoV-2 D614G N501Y variant and protect mice","volume":"118","author":"Pymm","year":"2021","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"13","key":"10.1016\/j.bea.2022.100054_bib0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.109292","article-title":"Recurrent emergence of SARS-CoV-2 spike deletion H69\/V70 and its role in the Alpha variant B.1.1.7","volume":"35","author":"Meng","year":"2021","journal-title":"Cell Rep."},{"issue":"7854","key":"10.1016\/j.bea.2022.100054_bib0046","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1038\/s41586-021-03402-9","article-title":"Detection of a SARS-CoV-2 variant of concern in South Africa","volume":"592","author":"Tegally","year":"2021","journal-title":"Nature"},{"issue":"6544","key":"10.1016\/j.bea.2022.100054_bib0047","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1126\/science.abh2644","article-title":"Genomics and epidemiology of the P.1 SARS-CoV-2 lineage in Manaus, Brazil","volume":"372","author":"Faria","year":"2021","journal-title":"Science"},{"issue":"7","key":"10.1016\/j.bea.2022.100054_bib0048","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.3390\/microorganisms9071542","article-title":"SARS-CoV-2 spike mutations, L452R, T478K, E484Q and P681R, in the second wave of COVID-19 in Maharashtra, India","volume":"9","author":"Cherian","year":"2021","journal-title":"Microorganisms"},{"key":"10.1016\/j.bea.2022.100054_bib0049","unstructured":"CDC. Science brief: Omicron (B.1.1.529) variant. 2021 15 January 2022]; Available from: https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/science\/science-briefs\/scientific-brief-omicron-variant.html."},{"key":"10.1016\/j.bea.2022.100054_bib0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.gene.2021.146134","article-title":"From Delta to Omicron: S1-RBD\/S2 mutation\/deletion equilibrium in SARS-CoV-2 defined variants","volume":"814","author":"Papanikolaou","year":"2022","journal-title":"Gene"},{"issue":"4540","key":"10.1016\/j.bea.2022.100054_bib0051","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1126\/science.7041255","article-title":"Rapid evolution of RNA genomes","volume":"215","author":"Holland","year":"1982","journal-title":"Science"},{"key":"10.1016\/j.bea.2022.100054_bib0052","doi-asserted-by":"crossref","unstructured":"Quinlan, B.D., et\u00a0al., The SARS-CoV-2 receptor-binding domain elicits a potent neutralizing response without antibody-dependent enhancement. IMMUNITY-D-20-00389, 2020.","DOI":"10.1101\/2020.04.10.036418"},{"issue":"20","key":"10.1016\/j.bea.2022.100054_bib0053","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1056\/NEJMoa030747","article-title":"Identification of a novel coronavirus in patients with severe acute respiratory syndrome","volume":"348","author":"Drosten","year":"2003","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.bea.2022.100054_bib0054","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.prrv.2004.07.011","article-title":"Epidemiology of severe acute respiratory syndrome (SARS): adults and children","volume":"5","author":"Zhong","year":"2004","journal-title":"Paediatr. Respir. Rev."},{"key":"10.1016\/j.bea.2022.100054_bib0055","unstructured":"WHO. Middle East respiratory syndrome. 2022 5 September 2022]; Available from: http:\/\/www.emro.who.int\/health-topics\/mers-cov\/mers-outbreaks.html."},{"issue":"2","key":"10.1016\/j.bea.2022.100054_bib0056","doi-asserted-by":"crossref","first-page":"e2171","DOI":"10.1002\/rmv.2171","article-title":"The unique features of SARS-CoV-2 transmission: comparison with SARS-CoV, MERS-CoV and 2009 H1N1 pandemic influenza virus","volume":"31","author":"Wu","year":"2021","journal-title":"Rev. Med. Virol."},{"issue":"7809","key":"10.1016\/j.bea.2022.100054_bib0057","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/s41586-020-2196-x","article-title":"Virological assessment of hospitalized patients with COVID-2019","volume":"581","author":"W\u00f6lfel","year":"2020","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.bea.2022.100054_bib0058","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.jmii.2020.02.001","article-title":"Emerging threats from zoonotic coronaviruses-from SARS and MERS to 2019-nCoV","volume":"53","author":"Lee","year":"2020","journal-title":"J. Microbiol. Immunol. Infect."},{"issue":"5","key":"10.1016\/j.bea.2022.100054_bib0059","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1007\/s10875-021-00997-6","article-title":"Serologic cross-reactivity of SARS-CoV-2 with endemic and seasonal betacoronaviruses","volume":"41","author":"Hicks","year":"2021","journal-title":"J. Clin. Immunol."},{"key":"10.1016\/j.bea.2022.100054_bib0060","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1146\/annurev-virology-110615-042301","article-title":"Structure, function, and evolution of coronavirus spike proteins","volume":"3","author":"Li","year":"2016","journal-title":"Annu. Rev. Virol."},{"issue":"6965","key":"10.1016\/j.bea.2022.100054_bib0061","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/nature02145","article-title":"Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus","volume":"426","author":"Li","year":"2003","journal-title":"Nature"},{"issue":"7440","key":"10.1016\/j.bea.2022.100054_bib0062","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/nature12005","article-title":"Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC","volume":"495","author":"Raj","year":"2013","journal-title":"Nature"},{"issue":"7807","key":"10.1016\/j.bea.2022.100054_bib0063","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/s41586-020-2180-5","article-title":"Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor","volume":"581","author":"Lan","year":"2020","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.bea.2022.100054_bib0064","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/j.chom.2020.04.023","article-title":"Identification of human single-domain antibodies against SARS-CoV-2","volume":"27","author":"Wu","year":"2020","journal-title":"Cell Host Microbe"},{"issue":"6501","key":"10.1016\/j.bea.2022.100054_bib0065","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1126\/science.abb9983","article-title":"Site-specific glycan analysis of the SARS-CoV-2 spike","volume":"369","author":"Watanabe","year":"2020","journal-title":"Science"},{"issue":"21","key":"10.1016\/j.bea.2022.100054_bib0066","doi-asserted-by":"crossref","first-page":"11727","DOI":"10.1073\/pnas.2003138117","article-title":"Cell entry mechanisms of SARS-CoV-2","volume":"117","author":"Shang","year":"2020","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.bea.2022.100054_bib0067","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.ijbiomac.2020.01.039","article-title":"Diagnostic and therapeutic potential of shark variable new antigen receptor (VNAR) single domain antibody","volume":"147","author":"Cheong","year":"2020","journal-title":"Int. J. Biol. Macromol."},{"issue":"1","key":"10.1016\/j.bea.2022.100054_bib0068","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-020-18387-8","article-title":"Humanized single domain antibodies neutralize SARS-CoV-2 by targeting the spike receptor binding domain","volume":"11","author":"Chi","year":"2020","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.bea.2022.100054_bib0069","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.jchromb.2006.07.004","article-title":"Antibody production: polyclonal-derived biotherapeutics","volume":"848","author":"Newcombe","year":"2007","journal-title":"J. Chromatogr. B"},{"issue":"4","key":"10.1016\/j.bea.2022.100054_bib0070","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1172\/JCI138003","article-title":"The convalescent sera option for containing COVID-19","volume":"130","author":"Casadevall","year":"2020","journal-title":"J. Clin. Investig."},{"issue":"7","key":"10.1016\/j.bea.2022.100054_bib0071","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2020.102554","article-title":"Convalescent plasma in COVID-19: possible mechanisms of action","volume":"19","author":"Rojas","year":"2020","journal-title":"Autoimmun. Rev."},{"issue":"1","key":"10.1016\/j.bea.2022.100054_bib0072","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.cell.2020.05.025","article-title":"Potent neutralizing antibodies against SARS-CoV-2 identified by high-throughput single-cell sequencing of convalescent patients\u2019 B cells","volume":"182","author":"Cao","year":"2020","journal-title":"Cell"},{"issue":"7819","key":"10.1016\/j.bea.2022.100054_bib0073","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/s41586-020-2380-z","article-title":"Human neutralizing antibodies elicited by SARS-CoV-2 infection","volume":"584","author":"Ju","year":"2020","journal-title":"Nature"},{"issue":"6506","key":"10.1016\/j.bea.2022.100054_bib0074","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1126\/science.abc7520","article-title":"Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model","volume":"369","author":"Rogers","year":"2020","journal-title":"Science"},{"issue":"7819","key":"10.1016\/j.bea.2022.100054_bib0075","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1038\/s41586-020-2381-y","article-title":"A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2","volume":"584","author":"Shi","year":"2020","journal-title":"Nature"},{"issue":"7821","key":"10.1016\/j.bea.2022.100054_bib0076","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/s41586-020-2548-6","article-title":"Potently neutralizing and protective human antibodies against SARS-CoV-2","volume":"584","author":"Zost","year":"2020","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.bea.2022.100054_bib0077","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1111\/j.1432-1033.1981.tb05538.x","article-title":"12th Sir Hans Krebs lecture from antibody diversity to monoclonal antibodies","volume":"118","author":"Milstein","year":"1981","journal-title":"Eur. J. Biochem."},{"issue":"10","key":"10.1016\/j.bea.2022.100054_bib0078","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.7150\/ijbs.45123","article-title":"Perspectives on therapeutic neutralizing antibodies against the novel coronavirus SARS-CoV-2","volume":"16","author":"Zhou","year":"2020","journal-title":"Int. J. Biol. Sci."},{"issue":"18","key":"10.1016\/j.bea.2022.100054_bib0079","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1007\/s40265-021-01626-7","article-title":"Regdanvimab: first approval","volume":"81","author":"Syed","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.bea.2022.100054_bib0080","doi-asserted-by":"crossref","first-page":"4998","DOI":"10.3389\/fimmu.2021.772320","article-title":"Effectiveness of regdanvimab treatment in high-risk COVID-19 patients to prevent progression to severe disease","volume":"12","author":"Lee","year":"2021","journal-title":"Front. Immunol."},{"issue":"3","key":"10.1016\/j.bea.2022.100054_bib0081","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1056\/NEJMoa2029849","article-title":"SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with COVID-19","volume":"384","author":"Chen","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.bea.2022.100054_bib0082","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1056\/NEJMoa2035002","article-title":"REGN-COV2, a neutralizing antibody cocktail, in outpatients with COVID-19","volume":"384","author":"Weinreich","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.bea.2022.100054_bib0083","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/nrd2153","article-title":"Inhaling medicines: delivering drugs to the body through the lungs","volume":"6","author":"Patton","year":"2007","journal-title":"Nat. Rev. Drug Discov."},{"issue":"7821","key":"10.1016\/j.bea.2022.100054_bib0084","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/d41586-020-02360-y","article-title":"Antibody therapies could be a bridge to a coronavirus vaccine-but will the world benefit?","volume":"584","author":"Ledford","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.bea.2022.100054_bib0085","series-title":"Antibody Fragments: Hope and Hype. In MAbs","first-page":"77","volume":"2","author":"Nelson","year":"2010"},{"issue":"6428","key":"10.1016\/j.bea.2022.100054_bib0086","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1038\/363446a0","article-title":"Naturally occurring antibodies devoid of light chains","volume":"363","author":"Hamers-Casterman","year":"1993","journal-title":"Nature"},{"issue":"12","key":"10.1016\/j.bea.2022.100054_bib0087","doi-asserted-by":"crossref","first-page":"4586","DOI":"10.1073\/pnas.0505379103","article-title":"Molecular basis for the preferential cleft recognition by dromedary heavy-chain antibodies","volume":"103","author":"De Genst","year":"2006","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"1","key":"10.1016\/j.bea.2022.100054_bib0088","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12936-018-2531-y","article-title":"Isolation and characterization of malaria PfHRP2 specific VNAR antibody fragments from immunized shark phage display library","volume":"17","author":"Leow","year":"2018","journal-title":"Malar. J."},{"issue":"2","key":"10.1016\/j.bea.2022.100054_bib0089","first-page":"81","article-title":"Nanobodies: emerging tools for clinical applications","volume":"4","author":"Aghebati-Maleki","year":"2018","journal-title":"J. Res. Appl. Basic Med. Sci."},{"issue":"6","key":"10.1016\/j.bea.2022.100054_bib0090","first-page":"1069","article-title":"Progress in shark single-domain antibody","volume":"36","author":"Liu","year":"2020","journal-title":"Chin. J. Biotechnol."},{"key":"10.1016\/j.bea.2022.100054_bib0091","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1146\/annurev-biochem-063011-092449","article-title":"Nanobodies: natural single-domain antibodies","volume":"82","author":"Muyldermans","year":"2013","journal-title":"Annu. Rev. Biochem."},{"issue":"1","key":"10.1016\/j.bea.2022.100054_bib0092","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1128\/AAC.01802-15","article-title":"Generation and characterization of ALX-0171, a potent novel therapeutic nanobody for the treatment of respiratory syncytial virus infection","volume":"60","author":"Detalle","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"issue":"10","key":"10.1016\/j.bea.2022.100054_bib0093","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1517\/14712598.2014.937701","article-title":"Shark variable new antigen receptor biologics\u2013a novel technology platform for therapeutic drug development","volume":"14","author":"Kovaleva","year":"2014","journal-title":"Expert Opin. Biol. Ther."},{"key":"10.1016\/j.bea.2022.100054_bib0094","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.3389\/fimmu.2017.01802","article-title":"Single-domain antibodies as therapeutics against human viral diseases","volume":"8","author":"Wu","year":"2017","journal-title":"Front. Immunol."},{"issue":"49","key":"10.1016\/j.bea.2022.100054_bib0095","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/978-1-4419-1132-2_6","article-title":"Shark novel antigen receptors\u2014the next generation of biologic therapeutics?","volume":"655","author":"Barelle","year":"2009","journal-title":"Pharm. Biotechnol."},{"issue":"2","key":"10.1016\/j.bea.2022.100054_bib0096","first-page":"109","article-title":"Nanobodies: the future of antibody-based immune therapeutics","volume":"36","author":"Bathula","year":"2021","journal-title":"Cancer Biother. Radiopharm."},{"issue":"11","key":"10.1016\/j.bea.2022.100054_bib0097","doi-asserted-by":"crossref","first-page":"2901","DOI":"10.1110\/ps.051709505","article-title":"Structure of a shark IgNAR antibody variable domain and modeling of an early-developmental isotype","volume":"14","author":"Streltsov","year":"2005","journal-title":"Protein Sci."},{"issue":"6","key":"10.1016\/j.bea.2022.100054_bib0098","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1042\/BST20180177","article-title":"Next-generation flexible formats of VNAR domains expand the drug platform's utility and developability","volume":"46","author":"Ubah","year":"2018","journal-title":"Biochem. Soc. Trans."},{"issue":"3","key":"10.1016\/j.bea.2022.100054_bib0099","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/S0141-0229(01)00497-5","article-title":"Large-scale production of VHH antibody fragments by Saccharomyces cerevisiae","volume":"30","author":"Thomassen","year":"2002","journal-title":"Enzyme Microb. Technol."},{"issue":"1","key":"10.1016\/j.bea.2022.100054_bib0100","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s00253-007-1142-2","article-title":"Properties, production, and applications of camelid single-domain antibody fragments","volume":"77","author":"Harmsen","year":"2007","journal-title":"Appl. Microbiol. Biotechnol."},{"key":"10.1016\/j.bea.2022.100054_bib0101","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.3389\/fimmu.2017.01780","article-title":"Novel, anti-hTNF-\u03b1 variable new antigen receptor formats with enhanced neutralizing potency and multifunctionality, generated for therapeutic development","volume":"8","author":"Ubah","year":"2017","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.bea.2022.100054_bib0102","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-020-18174-5","article-title":"An alpaca nanobody neutralizes SARS-CoV-2 by blocking receptor interaction","volume":"11","author":"Hanke","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bea.2022.100054_bib0103","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.3389\/fimmu.2017.01603","article-title":"Nanobodies and nanobody-based human heavy chain antibodies as antitumor therapeutics","volume":"8","author":"Bannas","year":"2017","journal-title":"Front. Immunol."},{"issue":"4","key":"10.1016\/j.bea.2022.100054_bib0104","doi-asserted-by":"crossref","first-page":"52","DOI":"10.3390\/diagnostics7040052","article-title":"Single domain antibodies as new biomarker detectors","volume":"7","author":"Leow","year":"2017","journal-title":"Diagnostics"},{"issue":"3","key":"10.1016\/j.bea.2022.100054_bib0105","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1110\/ps.34602","article-title":"Single-domain antibody fragments with high conformational stability","volume":"11","author":"Dumoulin","year":"2002","journal-title":"Protein Sci."},{"issue":"1","key":"10.1016\/j.bea.2022.100054_bib0106","doi-asserted-by":"crossref","first-page":"66","DOI":"10.3390\/antib2010066","article-title":"Shark variable new antigen receptor (VNAR) single domain antibody fragments: stability and diagnostic applications","volume":"2","author":"Griffiths","year":"2013","journal-title":"Antibodies"},{"issue":"8","key":"10.1016\/j.bea.2022.100054_bib0107","doi-asserted-by":"crossref","first-page":"2785","DOI":"10.1016\/j.ymthe.2022.04.013","article-title":"A highly stable human single-domain antibody-drug conjugate exhibits superior penetration and treatment of solid tumors","volume":"30","author":"Wu","year":"2022","journal-title":"Mol. Ther."},{"key":"10.1016\/j.bea.2022.100054_bib0108","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.3389\/fimmu.2017.01361","article-title":"In vitro maturation of a humanized shark VNAR domain to improve its biophysical properties to facilitate clinical development","volume":"8","author":"Steven","year":"2017","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bea.2022.100054_bib0109","unstructured":"Ardekani, L.S., et\u00a0al., Characterization of physical chemical properties of nanobody against Helicobacter Pylori urease. 2022."},{"issue":"3401","key":"10.1016\/j.bea.2022.100054_bib0110","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1126\/science.131.3401.670","article-title":"Function of the rectal gland in the spiny dogfish","volume":"131","author":"Burger","year":"1960","journal-title":"Science"},{"issue":"5","key":"10.1016\/j.bea.2022.100054_bib0111","doi-asserted-by":"crossref","first-page":"3273","DOI":"10.1074\/jbc.M806889200","article-title":"General strategy to humanize a camelid single-domain antibody and identification of a universal humanized nanobody scaffold","volume":"284","author":"Vincke","year":"2009","journal-title":"J. Biol. Chem."},{"issue":"24","key":"10.1016\/j.bea.2022.100054_bib0112","doi-asserted-by":"crossref","first-page":"17408","DOI":"10.1074\/jbc.M112.435289","article-title":"Atypical antigen recognition mode of a shark immunoglobulin new antigen receptor (IgNAR) variable domain characterized by humanization and structural analysis","volume":"288","author":"Kovalenko","year":"2013","journal-title":"J. Biol. Chem."},{"issue":"6523","key":"10.1016\/j.bea.2022.100054_bib0113","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1126\/science.abe4747","article-title":"Versatile and multivalent nanobodies efficiently neutralize SARS-CoV-2","volume":"370","author":"Xiang","year":"2020","journal-title":"Science"},{"issue":"12","key":"10.1016\/j.bea.2022.100054_bib0114","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.3390\/biom10121661","article-title":"Picomolar SARS-CoV-2 neutralization using multi-arm PEG nanobody constructs","volume":"10","author":"Moliner-Morro","year":"2020","journal-title":"Biomolecules"},{"issue":"8","key":"10.1016\/j.bea.2022.100054_bib0115","doi-asserted-by":"crossref","first-page":"464","DOI":"10.3390\/toxins11080464","article-title":"Camelid VHHs fused to human Fc fragments provide long term protection against botulinum neurotoxin a in mice","volume":"11","author":"Godakova","year":"2019","journal-title":"Toxins"},{"issue":"3","key":"10.1016\/j.bea.2022.100054_bib0116","doi-asserted-by":"crossref","first-page":"745","DOI":"10.3390\/molecules25030745","article-title":"The pharmaceutical industry in 2019. An analysis of FDA drug approvals from the perspective of molecules","volume":"25","author":"de la Torre","year":"2020","journal-title":"Molecules"},{"issue":"7","key":"10.1016\/j.bea.2022.100054_bib0117","first-page":"871","article-title":"Counting the cost of caplacizumab","volume":"137","author":"Chaturvedi","year":"2021","journal-title":"Blood J. Am. Soc. Hematol."},{"key":"10.1016\/j.bea.2022.100054_bib0118","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.pharmthera.2016.06.012","article-title":"Nanobodies\u00ae as inhaled biotherapeutics for lung diseases","volume":"169","author":"Van Heeke","year":"2017","journal-title":"Pharmacol. Ther."},{"issue":"1","key":"10.1016\/j.bea.2022.100054_bib0119","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S2213-2600(20)30320-9","article-title":"Nebulised ALX-0171 for respiratory syncytial virus lower respiratory tract infection in hospitalised children: a double-blind, randomised, placebo-controlled, phase 2b trial","volume":"9","author":"Cunningham","year":"2021","journal-title":"Lancet Respir. Med."},{"issue":"1","key":"10.1016\/j.bea.2022.100054_bib0120","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-020-19204-y","article-title":"Selection, biophysical and structural analysis of synthetic nanobodies that effectively neutralize SARS-CoV-2","volume":"11","author":"Cust\u00f3dio","year":"2020","journal-title":"Nat. Commun."},{"issue":"6523","key":"10.1016\/j.bea.2022.100054_bib0121","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1126\/science.abe3255","article-title":"An ultrapotent synthetic nanobody neutralizes SARS-CoV-2 by stabilizing inactive spike","volume":"370","author":"Schoof","year":"2020","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.bea.2022.100054_bib0122","first-page":"1","article-title":"Potent neutralization of clinical isolates of SARS-CoV-2 D614 and G614 variants by a monomeric, sub-nanomolar affinity nanobody","volume":"11","author":"Nieto","year":"2021","journal-title":"Sci. Rep."},{"issue":"6301","key":"10.1016\/j.bea.2022.100054_bib0123","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/348552a0","article-title":"Phage antibodies: filamentous phage displaying antibody variable domains","volume":"348","author":"McCafferty","year":"1990","journal-title":"Nature"},{"key":"10.1016\/j.bea.2022.100054_bib0124","series-title":"Camelid Ig V Genes Reveal Significant Human Homology Not Seen in Therapeutic Target Genes, Providing for a Powerful Therapeutic Antibody Platform. In MAbs","first-page":"693","volume":"7 (4)","author":"Klarenbeek","year":"2015"},{"issue":"5","key":"10.1016\/j.bea.2022.100054_bib0125","doi-asserted-by":"crossref","DOI":"10.21037\/atm.2019.01.42","article-title":"NK-mediated antibody-dependent cell-mediated cytotoxicity in solid tumors: biological evidence and clinical perspectives","volume":"7","author":"Nigro","year":"2019","journal-title":"Ann. Transl. Med."},{"key":"10.1016\/j.bea.2022.100054_bib0126","doi-asserted-by":"crossref","first-page":"332","DOI":"10.3389\/fimmu.2019.00332","article-title":"Antibody-dependent cellular phagocytosis in antiviral immune responses","volume":"10","author":"Tay","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bea.2022.100054_bib0127","doi-asserted-by":"crossref","first-page":"548","DOI":"10.3389\/fimmu.2019.00548","article-title":"Fc-mediated antibody effector functions during respiratory syncytial virus infection and disease","volume":"10","author":"Van Erp","year":"2019","journal-title":"Front. Immunol."},{"issue":"6","key":"10.1016\/j.bea.2022.100054_bib0128","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1038\/s41577-020-0321-6","article-title":"The potential danger of suboptimal antibody responses in COVID-19","volume":"20","author":"Iwasaki","year":"2020","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.bea.2022.100054_bib0129","series-title":"D614G Mutation Eventuates in all VOI and VOC in SARS-CoV-2: is it Part of the Positive Selection Pioneered by Darwin?","first-page":"237","volume":"26","author":"Chakraborty","year":"2021"},{"issue":"9","key":"10.1016\/j.bea.2022.100054_bib0130","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1021\/acsmedchemlett.0c00410","article-title":"Structural impact of mutation D614G in SARS-CoV-2 spike protein: enhanced infectivity and therapeutic opportunity","volume":"11","author":"Fern\u00e1ndez","year":"2020","journal-title":"ACS Med. Chem. Lett."},{"issue":"7852","key":"10.1016\/j.bea.2022.100054_bib0131","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/s41586-020-2895-3","article-title":"Spike mutation D614G alters SARS-CoV-2 fitness","volume":"592","author":"Plante","year":"2021","journal-title":"Nature"},{"issue":"6523","key":"10.1016\/j.bea.2022.100054_bib0132","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1126\/science.abe8499","article-title":"SARS-CoV-2 D614G variant exhibits efficient replication ex vivo and transmission in vivo","volume":"370","author":"Hou","year":"2020","journal-title":"Science"},{"issue":"4","key":"10.1016\/j.bea.2022.100054_bib0133","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/j.cell.2020.06.043","article-title":"Tracking changes in SARS-CoV-2 spike: evidence that D614G increases infectivity of the COVID-19 virus","volume":"182","author":"Korber","year":"2020","journal-title":"Cell"},{"issue":"8","key":"10.1016\/j.bea.2022.100054_bib0134","article-title":"Engineered multivalent nanobodies potently and broadly neutralize SARS-CoV-2 variants","volume":"4","author":"Zupancic","year":"2021","journal-title":"Adv. Ther."},{"issue":"11","key":"10.1016\/j.bea.2022.100054_bib0135","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1099\/jgv.0.001481","article-title":"SARS-CoV-2 growth, furin-cleavage-site adaptation and neutralization using serum from acutely infected hospitalized COVID-19 patients","volume":"101","author":"Klimstra","year":"2020","journal-title":"J. Gen. Virol."},{"issue":"3","key":"10.1016\/j.bea.2022.100054_bib0136","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1038\/nprot.2014.039","article-title":"A general protocol for the generation of nanobodies for structural biology","volume":"9","author":"Pardon","year":"2014","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.bea.2022.100054_bib0137","doi-asserted-by":"crossref","DOI":"10.1016\/j.meegid.2020.104260","article-title":"Genetic diversity and evolution of SARS-CoV-2","volume":"81","author":"Phan","year":"2020","journal-title":"Infect. Genet. Evol."},{"key":"10.1016\/j.bea.2022.100054_bib0138","first-page":"409","article-title":"Structural and functional implications of spike protein mutational landscape in SARS-CoV-2","volume":"19","author":"Nelson-Sathi","year":"2021","journal-title":"Nature Reviews Microbiology"},{"key":"10.1016\/j.bea.2022.100054_bib0139","article-title":"Emergence of RBD mutations in circulating SARS-CoV-2 strains enhancing the structural stability and human ACE2 receptor affinity of the spike protein","author":"Ou","year":"2020","journal-title":"bioRxiv"},{"issue":"6","key":"10.1016\/j.bea.2022.100054_bib0140","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1111\/1751-7915.12819","article-title":"Escherichia coli surface display for the selection of nanobodies","volume":"10","author":"Salema","year":"2017","journal-title":"Microb. Biotechnol."},{"issue":"1","key":"10.1016\/j.bea.2022.100054_bib0141","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES.2020.26.1.2002106","article-title":"Early transmissibility assessment of the N501Y mutant strains of SARS-CoV-2 in the United Kingdom, October to November 2020","volume":"26","author":"Leung","year":"2021","journal-title":"Eurosurveillance"},{"key":"10.1016\/j.bea.2022.100054_bib0142","series-title":"Tracking the International Spread of SARS-CoV-2 Lineages B. 1.1. 7 and B. 1.351\/501Y-V2","first-page":"6","author":"O'Toole","year":"2021"},{"key":"10.1016\/j.bea.2022.100054_bib0143","series-title":"Phylogenetic Relationship of SARS-CoV-2 Sequences from Amazonas with Emerging Brazilian Variants Harboring Mutations E484K and N501Y in the Spike Protein","author":"Naveca","year":"2021"},{"issue":"4","key":"10.1016\/j.bea.2022.100054_bib0144","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/s41591-020-0820-9","article-title":"The proximal origin of SARS-CoV-2","volume":"26","author":"Andersen","year":"2020","journal-title":"Nat. Med."},{"issue":"7","key":"10.1016\/j.bea.2022.100054_bib0145","doi-asserted-by":"crossref","first-page":"e00120","DOI":"10.1128\/JVI.00127-20","article-title":"Receptor recognition by the novel coronavirus from Wuhan: an analysis based on decade-long structural studies of SARS coronavirus","volume":"94","author":"Wan","year":"2020","journal-title":"J. Virol."},{"issue":"10","key":"10.1016\/j.bea.2022.100054_bib0146","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1002\/1873-3468.14076","article-title":"Enhanced binding of the N501Y-mutated SARS-CoV-2 spike protein to the human ACE2 receptor: insights from molecular dynamics simulations","volume":"595","author":"Luan","year":"2021","journal-title":"FEBS Lett."},{"key":"10.1016\/j.bea.2022.100054_bib0147","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2021.09.003","article-title":"The emergence and ongoing convergent evolution of the SARS-CoV-2 N501Y lineages","author":"Martin","year":"2021","journal-title":"Cell"},{"issue":"6530","key":"10.1016\/j.bea.2022.100054_bib0148","doi-asserted-by":"crossref","DOI":"10.1126\/science.abe6230","article-title":"Structure-guided multivalent nanobodies block SARS-CoV-2 infection and suppress mutational escape","volume":"371","author":"Koenig","year":"2021","journal-title":"Science"},{"issue":"7866","key":"10.1016\/j.bea.2022.100054_bib0149","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1038\/s41586-021-03676-z","article-title":"Nanobodies from camelid mice and llamas neutralize SARS-CoV-2 variants","volume":"595","author":"Xu","year":"2021","journal-title":"Nature"},{"issue":"11","key":"10.1016\/j.bea.2022.100054_bib0150","doi-asserted-by":"crossref","first-page":"e21970","DOI":"10.1096\/fj.202100986RR","article-title":"Single domain shark VNAR antibodies neutralize SARS-CoV-2 infection in vitro","volume":"35","author":"Gauhar","year":"2021","journal-title":"FASEB J."},{"key":"10.1016\/j.bea.2022.100054_bib0151","doi-asserted-by":"crossref","unstructured":"Wise, J., COVID-19: the E484K mutation and the risks it poses. 2021, British Medical Journal Publishing Group.","DOI":"10.1136\/bmj.n359"},{"key":"10.1016\/j.bea.2022.100054_bib0152","doi-asserted-by":"crossref","DOI":"10.1016\/S2666-5247(21)00068-9","article-title":"SARS-CoV-2 spike E484K mutation reduces antibody neutralisation","author":"Jangra","year":"2021","journal-title":"Lancet Microbe"},{"issue":"5","key":"10.1016\/j.bea.2022.100054_bib0153","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.3201\/eid2705.210191","article-title":"Genomic evidence of SARS-CoV-2 reinfection involving E484K spike mutation, Brazil","volume":"27","author":"Nonaka","year":"2021","journal-title":"Emerg. Infect. Dis."},{"issue":"1","key":"10.1016\/j.bea.2022.100054_bib0154","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-021-27611-y","article-title":"Mechanisms of SARS-CoV-2 neutralization by shark variable new antigen receptors elucidated through X-ray crystallography","volume":"12","author":"Ubah","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bea.2022.100054_bib0155","doi-asserted-by":"crossref","DOI":"10.1002\/smtd.202200387","article-title":"A class of shark-derived single-domain antibodies can broadly neutralize SARS-related coronaviruses and the structural basis of neutralization and Omicron escape","author":"Feng","year":"2022","journal-title":"Small Methods"},{"issue":"7839","key":"10.1016\/j.bea.2022.100054_bib0156","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1038\/s41586-020-2852-1","article-title":"SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies","volume":"588","author":"Barnes","year":"2020","journal-title":"Nature"},{"issue":"11","key":"10.1016\/j.bea.2022.100054_bib0157","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.3390\/v13112214","article-title":"Structural biology of nanobodies against the spike protein of SARS-CoV-2","volume":"13","author":"Tang","year":"2021","journal-title":"Viruses"},{"issue":"4","key":"10.1016\/j.bea.2022.100054_bib0158","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1039\/b901970g","article-title":"Cu-free click cycloaddition reactions in chemical biology","volume":"39","author":"Jewett","year":"2010","journal-title":"Chem. Soc. Rev."},{"issue":"2","key":"10.1016\/j.bea.2022.100054_bib0159","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1021\/acs.molpharmaceut.6b00964","article-title":"Conjugation to 10\u00a0kDa linear PEG extends serum half-life and preserves the receptor-binding ability of mmTRAIL with minimal stimulation of PEG-specific antibodies","volume":"14","author":"Nie","year":"2017","journal-title":"Mol. Pharm."},{"issue":"8","key":"10.1016\/j.bea.2022.100054_bib0160","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1038\/11717","article-title":"Therapeutic antibody fragments with prolonged in vivo half-lives","volume":"17","author":"Chapman","year":"1999","journal-title":"Nat. Biotechnol."},{"issue":"22","key":"10.1016\/j.bea.2022.100054_bib0161","doi-asserted-by":"crossref","first-page":"eabh0319","DOI":"10.1126\/sciadv.abh0319","article-title":"Inhalable nanobody (PiN-21) prevents and treats SARS-CoV-2 infections in Syrian hamsters at ultra-low doses","volume":"7","author":"Nambulli","year":"2021","journal-title":"Sci. Adv."}],"updated-by":[{"DOI":"10.1016\/j.bea.2023.100086","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000}}],"container-title":["Biomedical Engineering Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667099222000305?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667099222000305?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T11:04:10Z","timestamp":1778929450000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2667099222000305"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":161,"alternative-id":["S2667099222000305"],"URL":"https:\/\/doi.org\/10.1016\/j.bea.2022.100054","relation":{},"ISSN":["2667-0992"],"issn-type":[{"value":"2667-0992","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Single domain antibodies derived from ancient animals as broadly neutralizing agents for SARS-CoV-2 and other coronaviruses","name":"articletitle","label":"Article Title"},{"value":"Biomedical Engineering Advances","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bea.2022.100054","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"100054"}}